177 related articles for article (PubMed ID: 29648492)
1. Azacitidine effectively reduces
Takei T; Yokoyama K; Shimizu E; Konuma T; Takahashi S; Yamaguchi R; Imoto S; Miyano S; Tojo A
Leuk Lymphoma; 2018 Nov; 59(11):2755-2756. PubMed ID: 29648492
[No Abstract] [Full Text] [Related]
2. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
Müller-Thomas C; Rudelius M; Rondak IC; Haferlach T; Schanz J; Huberle C; Schmidt B; Blaser R; Kremer M; Peschel C; Germing U; Platzbecker U; Götze K
Haematologica; 2014 Oct; 99(10):e179-81. PubMed ID: 24972774
[No Abstract] [Full Text] [Related]
3. Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.
Claiborne J; Bandyopathyay D; Roberts C; Hawks K; Aziz M; Simmons G; Wiedl C; Chung H; Clark W; McCarty J; Toor A
Leuk Lymphoma; 2019 Nov; 60(11):2733-2743. PubMed ID: 31046498
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.
Woo J; Howard NP; Storer BE; Fang M; Yeung CC; Scott BL; Deeg HJ
Haematologica; 2017 Jun; 102(6):e216-e218. PubMed ID: 28209655
[No Abstract] [Full Text] [Related]
5. Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.
Villela L; Anders V; Bolaños-Meade J
Anticancer Drugs; 2010 Apr; 21(4):469. PubMed ID: 20216343
[No Abstract] [Full Text] [Related]
6. Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
Karakulska-Prystupiuk E; Drozd-Sokołowska J; Waszczuk-Gajda A; Stefaniak A; Dwilewicz-Trojaczek J; Kulikowska A; Chmarzyńska-Mróz E; Basak G; Paluszewska M; Boguradzki P; Jędrzejczak W
Transplant Proc; 2018 Sep; 50(7):2212-2217. PubMed ID: 30177138
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutations and azacitidine treatment: to be or not to be related?
Rigolin GM; Cuneo A
Leuk Res; 2014 Jul; 38(7):727-8. PubMed ID: 24836763
[No Abstract] [Full Text] [Related]
8. Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple
Lodé L; Ameur A; Coste T; Ménard A; Richebourg S; Gaillard JB; Le Bris Y; Béné MC; Lavabre-Bertrand T; Soussi T
Haematologica; 2018 Jan; 103(1):e13-e16. PubMed ID: 29079597
[No Abstract] [Full Text] [Related]
9. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.
Schroeder T; Czibere A; Platzbecker U; Bug G; Uharek L; Luft T; Giagounidis A; Zohren F; Bruns I; Wolschke C; Rieger K; Fenk R; Germing U; Haas R; Kröger N; Kobbe G
Leukemia; 2013 Jun; 27(6):1229-35. PubMed ID: 23314834
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
[TBL] [Abstract][Full Text] [Related]
13. Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis.
Berger D; Bauer K; Kornauth C; Gamperl S; Stefanzl G; Smiljkovic D; Sillaber C; Bettelheim P; Knöbl P; Schiefer AI; Greiner G; Thalhammer R; Hoermann G; Schwarzinger I; Staber PB; Sperr WR; Valent P
Neoplasia; 2021 Dec; 23(12):1183-1191. PubMed ID: 34731787
[TBL] [Abstract][Full Text] [Related]
14. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
[No Abstract] [Full Text] [Related]
15. Transplantation for MDS in the elderly: more evidence, or more bias?
Cutler C
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1320-1. PubMed ID: 22750646
[No Abstract] [Full Text] [Related]
16. Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies.
Maples KT; Sabo RT; McCarty JM; Toor AA; Hawks KG
Leuk Lymphoma; 2018 Dec; 59(12):2836-2841. PubMed ID: 29616863
[TBL] [Abstract][Full Text] [Related]
17. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.
Cleven AH; Nardi V; Ok CY; Goswami M; Dal Cin P; Zheng Z; Iafrate AJ; Abdul Hamid MA; Wang SA; Hasserjian RP
Mod Pathol; 2015 Apr; 28(4):552-63. PubMed ID: 25412846
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy.
Zeidan AM; Bewersdorf JP; Hasle V; Shallis RM; Thompson E; de Menezes DL; Rose S; Boss I; Halene S; Haferlach T; Fox B
Leukemia; 2023 Jan; 37(1):240-243. PubMed ID: 36437356
[No Abstract] [Full Text] [Related]
19. Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
Bories P; Prade N; Lagarde S; Cabarrou B; Largeaud L; Plenecassagnes J; Luquet I; De Mas V; Filleron T; Cassou M; Sarry A; Fornecker LM; Simand C; Bertoli S; Recher C; Delabesse E
PLoS One; 2020; 15(10):e0238795. PubMed ID: 33001991
[TBL] [Abstract][Full Text] [Related]
20. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.
Ettou S; Audureau E; Humbrecht C; Benet B; Jammes H; Clozel T; Bardet V; Lacombe C; Dreyfus F; Mayeux P; Solary E; Fontenay M
Leukemia; 2012 Oct; 26(10):2297-9. PubMed ID: 22743624
[No Abstract] [Full Text] [Related]
[Next] [New Search]
